---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012679"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2022-07-14T23:59:59+00:00"
generated_at: "2026-06-24T14:50:08.570322+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# EyePoint Pharmaceuticals appoints Karen Zaderej to Board of Directors

## Summary
- Karen Zaderej appointed to Board effective July 11, 2022, expanding board to eight members.
- She will serve on the Audit Committee; receives $45k annual retainer plus $10k for committee service.
- Granted 6,000 RSUs and option for 22,000 shares vesting over three years, exercise price at grant date closing price.
- Zaderej is President/CEO/Chair of AxoGen, bringing 35+ years biopharma and medical device experience.
- Company expects her insight to advance lead pipeline asset EYP-1901 for wet AMD.

## SEC filing metadata
- accession: 0000950170-22-012679
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2022-07-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017022012679/0000950170-22-012679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017022012679/eypt-20220711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012679
- JSON: https://secwatch.observer/filing/0000950170-22-012679.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012679.txt

## Key facts
- Executive change
  Karen Zaderej was appointed as Director at EyePoint, Inc..
  - Action: appointed
  - Role: Director
  source text: increased the size of the Board to eight members and appointed Karen Zaderej to fill the vacancy on the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017022012679/0000950170-22-012679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.